8-K: Clearside Faces Nasdaq Delisting, Board Chair Resigns

Clearside Biomedical received a delisting notice from Nasdaq due to its low stock price, while its Board Chairperson resigned.

Summary

• Clearside Biomedical, Inc. (CLSD) received a notice from Nasdaq on August 11, 2025, indicating its common stock is subject to delisting.
• The delisting threat stems from the company's failure to regain compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share, within the 180-calendar day grace period that expired on August 6, 2025.
• The company intends to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting of its securities.
• To regain compliance, the common stock's closing bid price must be at least $1.00 per share for 10 to 20 consecutive business days.
• On August 4, 2025, the company filed a proxy statement seeking stockholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-15 to address the bid price requirement.
• Anthony Gibney resigned as Chairperson and a member of the Board of Directors, effective August 11, 2025, due to his new role as Chief Financial and Business Officer at Aura Biosciences, Inc.
• Clay B. Thorp, a current Board member, was appointed to succeed Mr. Gibney as Chairperson of the Board, effective August 13, 2025.

Sentiment

Score: 3

Explanation: The delisting notice is a significant negative event, indicating severe compliance issues. While the company has a plan (hearing, reverse split), the outcome is uncertain, and the underlying stock performance is poor. The management change, while not contentious, adds to the instability.

Positives

• The company's intent to request a hearing will automatically stay any suspension or delisting of its common stock, allowing it to continue trading on Nasdaq during the hearings process.
• The company has a plan (reverse stock split) to address the minimum bid price requirement.

Negatives

• The company failed to meet Nasdaq's minimum bid price requirement of $1.00 per share for 30 consecutive business days.
• Received a formal delisting notice from Nasdaq.
• The company did not regain compliance within the 180-calendar day grace period.

Risks

• Potential delisting of the company's common stock from The Nasdaq Stock Market LLC.
• Inability to regain compliance with Nasdaq's Minimum Bid Price Requirement.
• Risks, uncertainties, and assumptions related to the trading price of the Common Stock.
• Uncertainty regarding stockholder approval of the proposed reverse stock split.

Future Outlook

The company expects its common stock to continue to be listed and traded on Nasdaq pending the conclusion of the hearings process. It intends to regain compliance with the Minimum Bid Price Requirement, primarily through a proposed reverse stock split, subject to stockholder approval.

Management Comments

• The company intends to timely request a hearing before the Nasdaq Hearings Panel.
• The company expects that its common stock will continue to be listed and traded on Nasdaq pending the conclusion of the hearings process.
• Mr. Gibney's resignation is not the result of any dispute or disagreement with the Company or the Board.

Industry Context

Companies, particularly in the biotech sector, often face challenges maintaining Nasdaq's minimum bid price requirement, especially during periods of clinical trial setbacks or broader market downturns. Reverse stock splits are a common strategy employed by companies to avoid delisting and maintain investor confidence, though they do not fundamentally change the company's valuation.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to a regulatory process with Nasdaq regarding its non-compliance with listing rules, which could lead to delisting.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the continued listing of the company's stock on Nasdaq and the potential impact of a reverse stock split on their holdings.
• Employees may experience uncertainty regarding the company's future and stock-based compensation.

Next Steps

• Timely request a hearing before the Nasdaq Hearings Panel.
• Seek stockholder approval for a reverse stock split at an upcoming meeting.
• Work to ensure the common stock's closing bid price is at least $1.00 per share for 10 to 20 consecutive business days to regain compliance.

Key Dates

Recommendation

The company faces an imminent delisting threat from Nasdaq, a severe negative event that significantly increases investment risk and uncertainty. While a hearing and reverse stock split are planned, their success is not guaranteed. The underlying issue of sustained low stock price indicates fundamental challenges. A seasoned investor would likely divest to avoid further potential losses and reallocate capital to more stable opportunities, given the high risk of delisting and the lack of clear positive catalysts.

Keywords

Clearside Biomedical, Nasdaq delisting, reverse stock split, minimum bid price, corporate governance, stock market compliance, biotechnology, CLSD